Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
about
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataThe transcriptional regulation of the human CYP2C genesUpdate and new trends in antiemetic therapy: the continuing need for novel therapies.Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatmentAprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.An approach to evaluating drug-nutrient interactions.Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Aprepitant: drug-drug interactions in perspective.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Pharmacologic management of postoperative nausea and vomiting.Use of high-dose cisplatin with aprepitant in an outpatient setting.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.Aprepitant and fosaprepitant drug interactions: a systematic review.Pharmacokinetic interaction between pazopanib and cisplatin regimen.In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populationsTwo cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy.Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.
P2860
Q28084970-1E3D366C-EC7C-476A-ACB1-40453015073BQ33597311-7D36C9E8-6AA9-4BE4-96EB-C5D376E10C47Q34143667-E8CD586A-6C79-4A4E-8CBB-45E2EA5B5BEEQ34146486-06591309-064B-40CF-AFB2-27ED1509FDA9Q34570873-48C69B31-DDA0-4263-8EA5-A2C8EE5D1ABCQ35024342-F2302AD8-AFED-45C1-91B8-656D83C06B0AQ35962019-0F5C1E51-488F-4C5B-97C5-7D015C13CE79Q36284018-76831C28-3DBA-46A8-9D5F-12D671399B5BQ36320632-629EB6A4-56B7-4B99-B58F-B4F1455413EEQ36920404-55426D8E-2C44-4EB3-8D24-3DE43E8D82ABQ37355479-34317235-048B-47AF-9687-E7E85A1C4948Q37636064-098FC072-4A14-4EF3-9430-C3874067C12AQ37757799-33343EFD-BC23-4372-9A92-6FD91CCDA209Q37854702-723B28B9-123C-430E-BBAD-2C1195AE185DQ37901057-BF9F83D2-BDEB-40B4-8015-DE7C923A5C7DQ37924902-E5CED6CB-F3D9-437D-AC48-76C742E20A0FQ38057372-DB22390F-35AD-4B59-B05E-D579A66B4B60Q38752456-682BA9FE-67F6-49B5-AAB7-4FFFA371ABF2Q39275766-B4A83C88-6E38-41F3-91F0-3D642ABE236BQ39282847-BDCF77CA-F5DA-48BC-8D3C-0A37759AE455Q40094748-117F1227-34D5-4250-BC0D-A7FFCA8E8A45Q40600601-2ED909B2-17BE-474B-A89C-A9D5AC4994F6Q41386264-4C19A28A-5B77-4507-9350-E9139640A950Q41994672-6A92E4B5-7B98-4278-AB16-9D959242F261Q45169488-76104905-6992-46DE-AC3F-ABDA040B9DF4Q46112124-0A2AAE9F-70EF-4489-AF02-0A24C3A7949BQ46530749-EFE31955-DCBB-47EC-B8E4-A27B7AE4101DQ46807641-D793CE1C-3679-46FF-B89F-B7F42A633E1BQ47885855-882C1C42-3D2F-49DE-B4CA-515F414ED87DQ48333205-6F4DF667-F01A-4D07-A673-A9E096560B7CQ53083182-F0022A68-D061-4850-AEF8-BC092522B77FQ55060909-E721A651-FC32-4E38-A317-BE9B02A4F597
P2860
Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@en
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@nl
type
label
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@en
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@nl
prefLabel
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@en
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@nl
P2093
P2860
P356
P1476
Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.
@en
P2093
Anup K Majumdar
Craig R Shadle
Cynthia Gargano
Judith K Evans
Kevin J Petty
Robert A Blum
Thomas E Bradstreet
P2860
P304
P356
10.1177/0091270003262950
P577
2004-03-01T00:00:00Z